Literature DB >> 24874414

Preoperative maximum oxygen consumption is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer.

Alessandro Brunelli1, Cecilia Pompili2, Michele Salati2, Majed Refai2, Rossana Berardi3, Paola Mazzanti3, Michela Tiberi3.   

Abstract

BACKGROUND: The objective of this investigation was to evaluate whether maximum oxygen consumption (VO2max) is a reliable prognostic factor after lung resection for pathologic stage I non-small cell lung cancer (NSCLC).
METHODS: Observational analysis of 157 patients undergoing pulmonary lobectomy or segmentectomy for pathologic stage I (T1 or T2-N0 only) NSCLC, with preoperative measurement of Vo2max and complete follow-up (2006-2011). Survival was calculated by the Kaplan-Meier method. The log-rank test was used to assess differences in survival between groups. The relationships between survival and several baseline and clinical variables were determined by Cox multivariate analyses.
RESULTS: The median follow-up time was 40 months. The average preoperative Vo2max was 16.1 mL/kg · min and 69% of predicted value. Sixty-two (40%) patients had a Vo2max below 60%. The median and 5-year overall survivals of patients with preoperative Vo2max above 60% were significantly longer than in those with Vo2max below 60% (median not reached vs 48 months: 73% vs 40%, p=0.0004). Cox regression model showed that an age older than 70 years (p=0.005, hazard ratio 2.3) and Vo2max below 60% (p=0.001, hazard ratio 2.4) were independent prognostic factors significantly associated with overall survival. Cancer-specific survival was also longer in patients with Vo2max above 60% (81% vs 61%, p=0.01).
CONCLUSIONS: Exercise tolerance may influence the physiologic outcomes associated with cancer that can potentially affect survival. Physical rehabilitation aimed at improving exercise tolerance can possibly improve the long-term prognosis after operations for lung cancer.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874414     DOI: 10.1016/j.athoracsur.2014.04.029

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer.

Authors:  Mark F Berry; Chi-Fu Jeffrey Yang; Matthew G Hartwig; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2015-05-16       Impact factor: 4.330

2.  Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer.

Authors:  Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott
Journal:  JACC CardioOncol       Date:  2022-06-21

3.  Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jessica M Scott; Emily C Zabor; Emily Schwitzer; Graeme J Koelwyn; Scott C Adams; Tormod S Nilsen; Chaya S Moskowitz; Konstantina Matsoukas; Neil M Iyengar; Chau T Dang; Lee W Jones
Journal:  J Clin Oncol       Date:  2018-06-12       Impact factor: 44.544

4.  Maximal voluntary ventilation and forced vital capacity of pulmonary function are independent prognostic factors in colorectal cancer patients: A retrospective study of 2323 cases in a single-center of China.

Authors:  Jiangpeng Wei; Ying Zhang; Pengfei Yu; Xiuqin Li; Xiangying Feng; Shisen Li; Gang Ji; Xiaohua Li
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

5.  Exercise interventions for people undergoing multimodal cancer treatment that includes surgery.

Authors:  Lisa A Loughney; Malcolm A West; Graham J Kemp; Michael Pw Grocott; Sandy Jack
Journal:  Cochrane Database Syst Rev       Date:  2018-12-11

6.  Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial.

Authors:  Jessica M Scott; Samantha M Thomas; James E Herndon; Pamela S Douglas; Anthony F Yu; Valerie Rusch; James Huang; Catherine Capaci; Jenna N Harrison; Kurtis J Stoeckel; Tormod Nilsen; Elisabeth Edvardsen; Meghan G Michalski; Neil D Eves; Lee W Jones
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-10-17       Impact factor: 12.910

7.  Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1.

Authors:  Jingyao Li; Yang Qiu; Junxiu Yi; Xi Liu; Shixin Zhang; Deli Tan; Tao Jing; Yi Liao; Meng Tang; Jie Liu; Haidong Wang
Journal:  J Oncol       Date:  2021-09-23       Impact factor: 4.375

8.  The Marsden Morbidity Index: the derivation and validation of a simple risk index scoring system using cardiopulmonary exercise testing variables to predict morbidity in high-risk patients having major cancer surgery.

Authors:  Z Nawoor-Quinn; A Oliver; R Raobaikady; K Mohammad; S Cone; R Kasivisvanathan
Journal:  Perioper Med (Lond)       Date:  2022-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.